LORLATINIB demonstrated encouraging activity in patients with anaplastic lymphoma kinase (ALK) driven neuroblastoma, with particularly strong responses observed in those harbouring ALK hotspot mutations, according to new preliminary findings from a cohort of 25 patients.
Lorlatinib Activity in ALK Driven Neuroblastoma
The study evaluated the clinical efficacy and safety of lorlatinib in 25 patients with ALK driven neuroblastoma. Among 17 evaluable patients, the objective response rate was 64.7%: 11/17 patients achieved an objective response. Investigators also reported notable activity in newly diagnosed high-risk disease. All six patients who received lorlatinib alongside induction chemotherapy achieved an objective response, suggesting potential value for the treatment in frontline management strategies.
The data also revealed substantial variation in response according to tumour molecular profile. Patients with ALK hotspot mutations alone demonstrated the highest level of benefit, with an objective response rate of 100%. In contrast, patients with concurrent MYCN amplification, rare ALK mutations, or ALK amplification experienced markedly lower efficacy: objective response rate 25.0%; p=0.006. These findings indicate that underlying genomic features may strongly influence sensitivity to lorlatinib in ALK driven neuroblastoma.
Molecular Features Influence Treatment Response
Researchers observed evidence of acquired resistance associated with potential bypass pathway alterations. Identified mechanisms included BRAF fusions, MET amplification, and NF1 mutations. However, the investigators noted that functional validation of these alterations has not yet been established.
The heterogeneity in response patterns highlights the complexity of treating ALK driven neuroblastoma and suggests that molecular stratification may play an important role in future therapeutic approaches. The preliminary data support the need for further investigation into resistance biology and patient selection strategies.
Pulmonary Toxicity Raises Safety Considerations
Safety findings also emerged during the analysis. Pulmonary toxicity was reported in patients receiving lorlatinib in combination with anti GD2 immunotherapy or chemotherapy.
Overall, the findings suggest that lorlatinib may offer meaningful clinical benefit for selected patients with ALK driven neuroblastoma, particularly those with ALK hotspot mutations. At the same time, the data underscore ongoing challenges related to treatment resistance and toxicity, both of which will require further investigation in future studies.
Reference
Xie W et al. Lorlatinib monotherapy or combination therapy in anaplastic lymphoma kinase–driven high-risk neuroblastoma. Npj Precis Onc. 2026; https://doi.org/10.1038/s41698-026-01487-x.
Featured image: H_Ko on Adobe Stock.
